Ask Warren

AprilBio

397030 · KOSDAQ · ₩397030 · 에이프릴바이오

₩12,400 ₩0 (0.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩0₩725M₩0₩0₩0₩2.2B₩6.8B₩0
Operating income−₩2.9B−₩2.2B−₩2B−₩2.5B−₩2.7B−₩110M₩3.7B−₩2.4B
Net income−₩2B₩201M−₩2.3B−₩5B−₩3.1B₩594M₩6.6B−₩3.1B
Net income to shareholders−₩2B₩201M−₩2.3B−₩5B−₩3.1B₩594M₩6.6B−₩3.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩98B₩99B₩97B₩97B₩97B₩101B₩100B₩96B
Current assets₩83B₩86B₩95B₩94B₩94B₩98B₩97B₩83B
Cash and equivalents₩7.4B₩6.4B₩7.1B₩4.7B₩5.4B₩5.7B₩3.3B₩7.3B
Total liabilities₩1.5B₩987M₩804M₩6.6B₩7.4B₩8.6B₩8.6B₩22B
Current liabilities₩1.2B₩782M₩542M₩6.4B₩7.3B₩8.5B₩8.5B₩22B
Borrowings₩769M₩428M₩0₩1.6B₩3.1B₩2.9B₩2.7B₩6.5B
Total equity₩97B₩98B₩96B₩90B₩90B₩92B₩91B₩74B
Shareholders' equity₩97B₩98B₩96B₩90B₩90B₩92B₩91B₩74B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩333M−₩2.1B−₩860M−₩2.1B₩936M−₩1.3B₩6B₩19B
Capital spending₩48M₩0₩0₩7M₩0₩35M₩27M₩0
Free cash flow₩285M−₩2.1B−₩860M−₩2.1B₩936M−₩1.4B₩5.9B₩19B
Dividends paid——₩0₩0₩0₩0₩0₩0

Consolidated where available. Amounts in won.

Also known as: AprilBio / 에이프릴바이오 / 397030 / KRX:397030

Source: KRX statistical information